A broad portfolio of synthetic, small molecule, oral, selective and high affinity 5-HT2B receptor antagonists have been developed and patented. These small molecules are in different development stages and have shown positive preclinical efficacy data in several in vitro and in vivo models of fibrosis, as well as favorable safety and pharmacokinetic profiles. As with AM1476, these compounds have shown potential to halt and reverse the progression of fibrosis, but each have different chemical and pharmacological properties.
